Eintrag weiter verarbeiten
Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
Gespeichert in:
Zeitschriftentitel: | Journal of Clinical Oncology |
---|---|
Personen und Körperschaften: | , , , , , |
In: | Journal of Clinical Oncology, 36, 2018, 6_suppl, S. 236-236 |
Format: | E-Article |
Sprache: | Englisch |
veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
Schlagwörter: |
author_facet |
Gadzinski, Adam J. Greene, Kirsten L Carroll, Peter Ryan, Charles J. Feng, Felix Y Hope, Tom Gadzinski, Adam J. Greene, Kirsten L Carroll, Peter Ryan, Charles J. Feng, Felix Y Hope, Tom |
---|---|
author |
Gadzinski, Adam J. Greene, Kirsten L Carroll, Peter Ryan, Charles J. Feng, Felix Y Hope, Tom |
spellingShingle |
Gadzinski, Adam J. Greene, Kirsten L Carroll, Peter Ryan, Charles J. Feng, Felix Y Hope, Tom Journal of Clinical Oncology Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. Cancer Research Oncology |
author_sort |
gadzinski, adam j. |
spelling |
Gadzinski, Adam J. Greene, Kirsten L Carroll, Peter Ryan, Charles J. Feng, Felix Y Hope, Tom 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2018.36.6_suppl.236 <jats:p> 236 </jats:p><jats:p> Background: Conventional imaging techniques infrequently detect the site of prostate cancer disease in men with biochemical recurrence following radical prostatectomy (RP). We examine the use of Gallium-68 Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) to determine the site of disease recurrence in these men. Methods: We retrospectively reviewed men with persistently detectable prostate specific antigen (PSA) and those with formal biochemical recurrence (PSA ≥ 0.2 ng/mL) following RP who underwent PSMA PET scan under our institution's prospective trials (NCT02918357 & NCT02611882). We assessed the location of detected recurrences, and examined the distribution of recurrence location (prostate bed, pelvic lymph nodes (LN), and extra-pelvic disease) according to PSA at time of PET scan. Results: One hundred and fifty-eight men underwent PSMA PET after RP, 46% of men had previously undergone either adjuvant or salvage radiation therapy. Eleven men (7%) had the scan for persistently detectable PSA < 0.2 and 93% of men had biochemical recurrence. At time of RP, 66% of men had ≥pT3a disease, 40% had positive surgical margins, and 18% had positive lymph nodes. Gleason grade at RP was ≤3+3 in 5% of men, 3+4 in 27%, 4+3 in 32% and ≥4+4 in 36%. Overall, 77% of men had a lesion detectable on PSMA PET. Men with higher PSA at time of scan had a higher prevalence of lesions, with all men PSA > 6.0 having at least one lesion on PSMA PET (Table). Overall, we found extra-pelvic lesions in 44% of all men, and 58% of men with PSA ≥ 1.0. These are areas not typically covered by salvage radiation fields. Conclusions: PSMA PET detects lesions in a high proportion of men with biochemical recurrence following RP, with many lesions outside of the pelvis. This may facilitate more precise targeting of treatment areas for these patients. Clinical trial information: NCT02918357. Clinical trial information: NCT02611882. [Table: see text] </jats:p> Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. Journal of Clinical Oncology |
doi_str_mv |
10.1200/jco.2018.36.6_suppl.236 |
facet_avail |
Online Free |
finc_class_facet |
Medizin |
format |
ElectronicArticle |
fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxOC4zNi42X3N1cHBsLjIzNg |
id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxOC4zNi42X3N1cHBsLjIzNg |
institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
imprint |
American Society of Clinical Oncology (ASCO), 2018 |
imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2018 |
issn |
0732-183X 1527-7755 |
issn_str_mv |
0732-183X 1527-7755 |
language |
English |
mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
match_str |
gadzinski2018detectionofprostatecancerlesionsusinggallium68psma11petinmenwithbiochemicalrecurrencefollowingradicalprostatectomy |
publishDateSort |
2018 |
publisher |
American Society of Clinical Oncology (ASCO) |
recordtype |
ai |
record_format |
ai |
series |
Journal of Clinical Oncology |
source_id |
49 |
title |
Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_unstemmed |
Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_full |
Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_fullStr |
Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_full_unstemmed |
Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_short |
Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_sort |
detection of prostate cancer lesions using gallium-68 psma-11 pet in men with biochemical recurrence following radical prostatectomy. |
topic |
Cancer Research Oncology |
url |
http://dx.doi.org/10.1200/jco.2018.36.6_suppl.236 |
publishDate |
2018 |
physical |
236-236 |
description |
<jats:p> 236 </jats:p><jats:p> Background: Conventional imaging techniques infrequently detect the site of prostate cancer disease in men with biochemical recurrence following radical prostatectomy (RP). We examine the use of Gallium-68 Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) to determine the site of disease recurrence in these men. Methods: We retrospectively reviewed men with persistently detectable prostate specific antigen (PSA) and those with formal biochemical recurrence (PSA ≥ 0.2 ng/mL) following RP who underwent PSMA PET scan under our institution's prospective trials (NCT02918357 & NCT02611882). We assessed the location of detected recurrences, and examined the distribution of recurrence location (prostate bed, pelvic lymph nodes (LN), and extra-pelvic disease) according to PSA at time of PET scan. Results: One hundred and fifty-eight men underwent PSMA PET after RP, 46% of men had previously undergone either adjuvant or salvage radiation therapy. Eleven men (7%) had the scan for persistently detectable PSA < 0.2 and 93% of men had biochemical recurrence. At time of RP, 66% of men had ≥pT3a disease, 40% had positive surgical margins, and 18% had positive lymph nodes. Gleason grade at RP was ≤3+3 in 5% of men, 3+4 in 27%, 4+3 in 32% and ≥4+4 in 36%. Overall, 77% of men had a lesion detectable on PSMA PET. Men with higher PSA at time of scan had a higher prevalence of lesions, with all men PSA > 6.0 having at least one lesion on PSMA PET (Table). Overall, we found extra-pelvic lesions in 44% of all men, and 58% of men with PSA ≥ 1.0. These are areas not typically covered by salvage radiation fields. Conclusions: PSMA PET detects lesions in a high proportion of men with biochemical recurrence following RP, with many lesions outside of the pelvis. This may facilitate more precise targeting of treatment areas for these patients. Clinical trial information: NCT02918357. Clinical trial information: NCT02611882. [Table: see text] </jats:p> |
container_issue |
6_suppl |
container_start_page |
236 |
container_title |
Journal of Clinical Oncology |
container_volume |
36 |
format_de105 |
Article, E-Article |
format_de14 |
Article, E-Article |
format_de15 |
Article, E-Article |
format_de520 |
Article, E-Article |
format_de540 |
Article, E-Article |
format_dech1 |
Article, E-Article |
format_ded117 |
Article, E-Article |
format_degla1 |
E-Article |
format_del152 |
Buch |
format_del189 |
Article, E-Article |
format_dezi4 |
Article |
format_dezwi2 |
Article, E-Article |
format_finc |
Article, E-Article |
format_nrw |
Article, E-Article |
_version_ |
1792333515541446658 |
geogr_code |
not assigned |
last_indexed |
2024-03-01T14:13:59.981Z |
geogr_code_person |
not assigned |
openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Detection+of+prostate+cancer+lesions+using+Gallium-68+PSMA-11+PET+in+men+with+biochemical+recurrence+following+radical+prostatectomy.&rft.date=2018-02-20&genre=article&issn=1527-7755&volume=36&issue=6_suppl&spage=236&epage=236&pages=236-236&jtitle=Journal+of+Clinical+Oncology&atitle=Detection+of+prostate+cancer+lesions+using+Gallium-68+PSMA-11+PET+in+men+with+biochemical+recurrence+following+radical+prostatectomy.&aulast=Hope&aufirst=Tom&rft_id=info%3Adoi%2F10.1200%2Fjco.2018.36.6_suppl.236&rft.language%5B0%5D=eng |
SOLR | |
_version_ | 1792333515541446658 |
author | Gadzinski, Adam J., Greene, Kirsten L, Carroll, Peter, Ryan, Charles J., Feng, Felix Y, Hope, Tom |
author_facet | Gadzinski, Adam J., Greene, Kirsten L, Carroll, Peter, Ryan, Charles J., Feng, Felix Y, Hope, Tom, Gadzinski, Adam J., Greene, Kirsten L, Carroll, Peter, Ryan, Charles J., Feng, Felix Y, Hope, Tom |
author_sort | gadzinski, adam j. |
container_issue | 6_suppl |
container_start_page | 236 |
container_title | Journal of Clinical Oncology |
container_volume | 36 |
description | <jats:p> 236 </jats:p><jats:p> Background: Conventional imaging techniques infrequently detect the site of prostate cancer disease in men with biochemical recurrence following radical prostatectomy (RP). We examine the use of Gallium-68 Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) to determine the site of disease recurrence in these men. Methods: We retrospectively reviewed men with persistently detectable prostate specific antigen (PSA) and those with formal biochemical recurrence (PSA ≥ 0.2 ng/mL) following RP who underwent PSMA PET scan under our institution's prospective trials (NCT02918357 & NCT02611882). We assessed the location of detected recurrences, and examined the distribution of recurrence location (prostate bed, pelvic lymph nodes (LN), and extra-pelvic disease) according to PSA at time of PET scan. Results: One hundred and fifty-eight men underwent PSMA PET after RP, 46% of men had previously undergone either adjuvant or salvage radiation therapy. Eleven men (7%) had the scan for persistently detectable PSA < 0.2 and 93% of men had biochemical recurrence. At time of RP, 66% of men had ≥pT3a disease, 40% had positive surgical margins, and 18% had positive lymph nodes. Gleason grade at RP was ≤3+3 in 5% of men, 3+4 in 27%, 4+3 in 32% and ≥4+4 in 36%. Overall, 77% of men had a lesion detectable on PSMA PET. Men with higher PSA at time of scan had a higher prevalence of lesions, with all men PSA > 6.0 having at least one lesion on PSMA PET (Table). Overall, we found extra-pelvic lesions in 44% of all men, and 58% of men with PSA ≥ 1.0. These are areas not typically covered by salvage radiation fields. Conclusions: PSMA PET detects lesions in a high proportion of men with biochemical recurrence following RP, with many lesions outside of the pelvis. This may facilitate more precise targeting of treatment areas for these patients. Clinical trial information: NCT02918357. Clinical trial information: NCT02611882. [Table: see text] </jats:p> |
doi_str_mv | 10.1200/jco.2018.36.6_suppl.236 |
facet_avail | Online, Free |
finc_class_facet | Medizin |
format | ElectronicArticle |
format_de105 | Article, E-Article |
format_de14 | Article, E-Article |
format_de15 | Article, E-Article |
format_de520 | Article, E-Article |
format_de540 | Article, E-Article |
format_dech1 | Article, E-Article |
format_ded117 | Article, E-Article |
format_degla1 | E-Article |
format_del152 | Buch |
format_del189 | Article, E-Article |
format_dezi4 | Article |
format_dezwi2 | Article, E-Article |
format_finc | Article, E-Article |
format_nrw | Article, E-Article |
geogr_code | not assigned |
geogr_code_person | not assigned |
id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxOC4zNi42X3N1cHBsLjIzNg |
imprint | American Society of Clinical Oncology (ASCO), 2018 |
imprint_str_mv | American Society of Clinical Oncology (ASCO), 2018 |
institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
issn | 0732-183X, 1527-7755 |
issn_str_mv | 0732-183X, 1527-7755 |
language | English |
last_indexed | 2024-03-01T14:13:59.981Z |
match_str | gadzinski2018detectionofprostatecancerlesionsusinggallium68psma11petinmenwithbiochemicalrecurrencefollowingradicalprostatectomy |
mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
physical | 236-236 |
publishDate | 2018 |
publishDateSort | 2018 |
publisher | American Society of Clinical Oncology (ASCO) |
record_format | ai |
recordtype | ai |
series | Journal of Clinical Oncology |
source_id | 49 |
spelling | Gadzinski, Adam J. Greene, Kirsten L Carroll, Peter Ryan, Charles J. Feng, Felix Y Hope, Tom 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2018.36.6_suppl.236 <jats:p> 236 </jats:p><jats:p> Background: Conventional imaging techniques infrequently detect the site of prostate cancer disease in men with biochemical recurrence following radical prostatectomy (RP). We examine the use of Gallium-68 Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) to determine the site of disease recurrence in these men. Methods: We retrospectively reviewed men with persistently detectable prostate specific antigen (PSA) and those with formal biochemical recurrence (PSA ≥ 0.2 ng/mL) following RP who underwent PSMA PET scan under our institution's prospective trials (NCT02918357 & NCT02611882). We assessed the location of detected recurrences, and examined the distribution of recurrence location (prostate bed, pelvic lymph nodes (LN), and extra-pelvic disease) according to PSA at time of PET scan. Results: One hundred and fifty-eight men underwent PSMA PET after RP, 46% of men had previously undergone either adjuvant or salvage radiation therapy. Eleven men (7%) had the scan for persistently detectable PSA < 0.2 and 93% of men had biochemical recurrence. At time of RP, 66% of men had ≥pT3a disease, 40% had positive surgical margins, and 18% had positive lymph nodes. Gleason grade at RP was ≤3+3 in 5% of men, 3+4 in 27%, 4+3 in 32% and ≥4+4 in 36%. Overall, 77% of men had a lesion detectable on PSMA PET. Men with higher PSA at time of scan had a higher prevalence of lesions, with all men PSA > 6.0 having at least one lesion on PSMA PET (Table). Overall, we found extra-pelvic lesions in 44% of all men, and 58% of men with PSA ≥ 1.0. These are areas not typically covered by salvage radiation fields. Conclusions: PSMA PET detects lesions in a high proportion of men with biochemical recurrence following RP, with many lesions outside of the pelvis. This may facilitate more precise targeting of treatment areas for these patients. Clinical trial information: NCT02918357. Clinical trial information: NCT02611882. [Table: see text] </jats:p> Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. Journal of Clinical Oncology |
spellingShingle | Gadzinski, Adam J., Greene, Kirsten L, Carroll, Peter, Ryan, Charles J., Feng, Felix Y, Hope, Tom, Journal of Clinical Oncology, Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy., Cancer Research, Oncology |
title | Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_full | Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_fullStr | Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_full_unstemmed | Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_short | Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
title_sort | detection of prostate cancer lesions using gallium-68 psma-11 pet in men with biochemical recurrence following radical prostatectomy. |
title_unstemmed | Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. |
topic | Cancer Research, Oncology |
url | http://dx.doi.org/10.1200/jco.2018.36.6_suppl.236 |